Breadcrumb Home Studies Studies Search Filter Research Area AllBrain and Mental HealthCure and ImmunotherapyTherapeuticsTuberculosis Study Status AllClosed to AccrualClosed to Follow UpConcludedEnrollingIn DevelopmentParticipants Off Study and Primary Analysis CompletedPending Sort Study Number AscStudy Number Desc Submit Search Showing 23 studies. IMPAACT 2053: Long-Acting Injectable Cabotegravir as Postnatal Prophylaxis During Breastfeeding: Safety, Tolerability, and Model Development for Implementation DAIDS Number 39282 Research Area Therapeutics Study Status In Development IMPAACT 2044: Phase IV Study of the Pharmacokinetics and Safety of Ceftriaxone and Benzathine Penicillin G During Pregnancy DAIDS Number 39132 Research Area Therapeutics Study Status Enrolling IMPAACT 2042: Tatelo Plus DAIDS Number 39076 Research Area Cure and Immunotherapy Study Status Closed to Accrual IMPAACT 2041: Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women with Hepatitis C with and without HIV DAIDS Number 39052 Research Area Therapeutics Study Status Enrolling IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age DAIDS Number 38932 Research Area Therapeutics Study Status Enrolling IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2019: Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less than 12 Years of Age DAIDS Number 38504 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2017: MOCHA DAIDS Number 30070 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2016: Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings DAIDS Number 38506 Research Area Brain and Mental Health Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2014: Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-infected Children and Adolescents DAIDS Number 34150 Research Area Treatment Study Status Concluded Pagination Current page 1 Page 2 Page 3 Next page Next
IMPAACT 2053: Long-Acting Injectable Cabotegravir as Postnatal Prophylaxis During Breastfeeding: Safety, Tolerability, and Model Development for Implementation DAIDS Number 39282 Research Area Therapeutics Study Status In Development
IMPAACT 2044: Phase IV Study of the Pharmacokinetics and Safety of Ceftriaxone and Benzathine Penicillin G During Pregnancy DAIDS Number 39132 Research Area Therapeutics Study Status Enrolling
IMPAACT 2042: Tatelo Plus DAIDS Number 39076 Research Area Cure and Immunotherapy Study Status Closed to Accrual
IMPAACT 2041: Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women with Hepatitis C with and without HIV DAIDS Number 39052 Research Area Therapeutics Study Status Enrolling
IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age DAIDS Number 38932 Research Area Therapeutics Study Status Enrolling
IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2019: Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less than 12 Years of Age DAIDS Number 38504 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2017: MOCHA DAIDS Number 30070 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2016: Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings DAIDS Number 38506 Research Area Brain and Mental Health Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2014: Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-infected Children and Adolescents DAIDS Number 34150 Research Area Treatment Study Status Concluded
